The anti-VEGF therapeutics market size was valued at USD 14.80 billion in 2025 and is projected to grow from USD 15.09 billion in 2026 to USD 18.13 billion by 2034, growing at a CAGR of 2.32% during the forecast period (2026-2034).
Download Free Sample Report To learn more about this report,
Development of higher-concentration anti-VEGF formulations drives a transition from monthly injections to extended dosing intervals of 12–16 weeks. This reduces patient treatment burden and clinic capacity pressure while enabling manufacturers to extend product lifecycles, support premium pricing, and strengthen brand loyalty against biosimilar competition.
Innovation in bispecific anti-VEGF therapies targeting additional pathways such as Ang-2 shifts treatment from single-pathway inhibition to multi-mechanism disease control. This improves outcomes for patients with suboptimal response to monotherapy and allows manufacturers to differentiate clinically, strengthen patent protection, and reduce direct price-based competition.
Investment in refillable ocular implants and sustained-release delivery systems transition anti-VEGF therapy from repeated intravitreal injections to device-assisted long-term drug delivery. This supports prolonged efficacy and encourages cross-disciplinary biologic-device development.
Increasing generation of real-world and registry-based clinical evidence shifts value from controlled trials to long-term, real-world outcomes. This strengthens payer confidence, improves formulary positioning, and supports wider adoption of advanced anti-VEGF therapies, thereby enhancing overall market growth.
Rising global prevalence of diabetes increases the incidence of diabetic retinopathy and diabetic macular edema, which are primary indications for anti-VEGF therapy. Improved screening raises diagnosis rates, resulting in sustained patient inflow and stable long-term demand for intravitreal biologics across developed and emerging markets.
Growing older population worldwide, particularly in high-income regions, increases the prevalence of neovascular age-related macular degeneration. This drives consistent treatment volumes and repeat injection demand, supporting recurring revenue models and steady market growth.
Wider adoption of advanced retinal imaging technologies and national screening programs improves early detection of macular diseases. Earlier diagnosis increases treatment initiation and expands the treated patient pool, which raises biologic utilization rates and supports higher procedural throughput in ophthalmology clinics.
Availability of structured reimbursement for physician-administered biologics in developed healthcare systems reduces patient out-of-pocket burden and improves adherence to long-term therapy. Reliable payer coverage supports predictable demand, premium pricing stability, and sustained market penetration for anti-VEGF products.
Price competition from biosimilars and off-label alternatives intensifies as lower-cost ranibizumab biosimilars and off-label anti-VEGF agents gain wider acceptance. Hospitals and payers prioritize budget control in procurement decisions, which reduces pricing flexibility for branded products and compresses manufacturer margins, thereby limiting revenue growth in price-sensitive markets.
High treatment frequency of intravitreal injections creates physical discomfort and logistical burdens for patients. Repeated clinic visits reduce adherence, especially among elderly and mobility-limited populations, which lowers long-term therapy persistence and weakens real-world treatment uptake, slowing overall market adoption.
Stringent regulatory and pharmacovigilance requirements for biologic ophthalmic therapies increase development and compliance complexity. Extended approval timelines, intensive post-marketing surveillance, and potential safety-related restrictions raise costs and delay market entry, which constrains rapid geographic expansion and limits near-term market growth.
Large underdiagnosed and undertreated retinal disease populations in emerging regions create a strong growth opportunity as tertiary eye care infrastructure and insurance coverage expand. Early entry allows manufacturers to establish physician familiarity and brand trust ahead of widespread biosimilar penetration, positioning companies to secure long-term volume growth as diagnosis and treatment rates rise.
Development of combination anti-VEGF therapies with corticosteroids or novel anti-inflammatory agents presents a lucrative growth opportunity by improving outcomes in complex or refractory retinal conditions. As these regimens reduce injection burden or enhance visual response, future adoption may increase among difficult-to-treat patient subgroups, enabling manufacturers to expand indication breadth and sustain differentiated portfolio growth.
Advancement of gene therapy approaches for sustained VEGF inhibition offers a long-term growth opportunity with the potential to shift retinal disease management toward one-time or infrequent treatments. In the future, successful gene-based solutions may create high-value treatment paradigms with durable efficacy, giving early investors first-mover advantages and redefining competitive dynamics in ocular biologics markets.
Request Customizationto receive a tailored report.
Eylea dominated the anti-VEGF therapeutics market with a 64.44% share in 2025, primarily due to its strong clinical efficacy, extended dosing intervals, and broad approval across multiple retinal disorders. Its ability to reduce treatment burden through less frequent injections has enhanced physician preference and patient compliance.
Vabysmo is expected to register the product segment, with a CAGR of 3.21% during the forecast period. The growth is driven by its dual-target mechanism addressing both VEGF and Ang-2 pathways. This differentiated approach offers improved durability and extended treatment intervals, making it useful for patients requiring long-term management.
Age-related macular degeneration led the disease type market with a share of 55.63% in 2025, as it represents one of the most prevalent causes of vision loss among the elderly population. The high global burden of neovascular age-related macular degeneration and the established role of anti-VEGF therapy as the standard of care drive substantial treatment demand.
The macular edema segment is expected to register a CAGR of 3.45% during the forecast period, supported by increasing incidence linked to diabetes and retinal vein occlusion. Improved diagnostic capabilities and growing awareness regarding early intervention are promoting timely treatment initiation, which further enhances market growth.
Speak to an Analystto discuss market opportunities.
The anti-VEGF therapeutics market in North America had a share of 67.08% in 2025. The market is supported by the high prevalence of age-related macular degeneration and diabetic retinopathy in the US and Canada. High cases of diabetes in the US reflect the increasing risk of diabetic macular edema, a key indication for anti-VEGF therapy. In addition, strong reimbursement coverage under Medicare Part B for physician-administered biologics ensures consistent treatment adherence in elderly populations. High retina specialist density and widespread optical coherence tomography usage across US ophthalmology clinics accelerate diagnosis and repeated intravitreal injection volumes, thereby driving sustained market revenue growth.
The anti-VEGF therapeutics market is anticipated to register the fastest CAGR of 4.32% during the forecast period. The growth is driven by demographic expansion and national retinal screening initiatives rather than reimbursement dominance. China’s National Health Commission has strengthened chronic disease management programs that include diabetic eye screening in urban hospitals, improving early case detection. India’s National Programme for Control of Blindness (NPCB) supports retinal screening camps, expanding the treatable patient pool for anti-VEGF injections. Japan contributes through its rapidly aging population, creating sustained demand for neovascular AMD treatment under universal health coverage. In Australia, the Pharmaceutical Benefits Scheme subsidizes selected anti-VEGF agents for wet AMD and diabetic macular edema, improving therapy affordability.
The anti-VEGF therapeutics market in Europe is growing due to strong regulatory oversight by the European Medicines Agency (EMA). The UK’s National Health Service provides coverage for approved anti-VEGF agents in wet AMD and diabetic macular edema, ensuring standardized treatment pathways. Additionally, increasing uptake of biosimilar ranibizumab across European markets supports cost containment strategies within national healthcare systems. Europe’s emphasis on pharmacovigilance and post-marketing surveillance under EMA regulations ensures sustained physician confidence in biologic ophthalmology products. Expansion of hospital-based ophthalmology units and retinal specialty networks across Western Europe further contributes to procedural volumes and market stability.
The Middle East & Africa market is progressing due to healthcare infrastructure modernization and the concentration of advanced ophthalmic services in metropolitan hubs. Under Saudi Arabia’s Vision 2030 healthcare transformation agenda, investment in specialty hospitals has increased access to advanced retinal therapies. The UAE has developed private super-specialty eye hospitals that actively offer branded anti-VEGF biologics to insured populations, which further fuels market growth.
The Latin American market is supported by the expansion of private ophthalmology chains and increasing incorporation of retinal services in urban tertiary hospitals. Rising urbanization and improved specialist training programs are strengthening retina subspecialty capacity across the region. Unlike other regions, growth here is more dependent on private sector expansion and out-of-pocket expenditure patterns, shaping a price-conscious yet steadily expanding anti-VEGF market landscape.
Unlock Regional Insightsto access country-level data, & regional trends.
The global anti-VEGF therapeutics market is characterized by a moderately consolidated structure, with a limited number of multinational biopharmaceutical companies accounting for a significant share of global revenues. The market comprises originator biologics manufacturers, biosimilar developers, and emerging biotechnology firms focused on next-generation ophthalmology and oncology biologics. Market participants increasingly compete on clinical differentiation, dosing durability, safety profile, and lifecycle management strategies, including high-dose formulations and expanded label indications.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a Healthcare Lead with over 7 years of industry experience, specializing in Healthcare IT. She provides comprehensive market insights on digital health, electronic medical records, telehealth, and healthcare analytics. Debashree’s research supports organizations in adopting technology-driven healthcare solutions, improving patient care, and achieving operational efficiency in a rapidly transforming healthcare ecosystem.
We are featured on:
sales@straitsresearch.com